The impact of surgical strategy and rifampin on treatment outcome in Cutibacterium periprosthetic joint infections

Autor: Rihard Trebše, Natalie Gassmann, Jaime Esteban, Benito Natividad, Bernhard Jost, Philipp Jent, Carol Strahm, Christine Thurnheer, Stéphane Corvec, Parham Sendi, Jaime Lora-Tamayo, Isabelle Waldmann, Tobias Kramer, Dorsaf Slama, Philippe Morand, Daniel Pablo-Marcos, Vincent A Stadelmann, Marta Fernandez-Sampedro, Yvonne Achermann, Robin Patel, Matteo Ferrari, Marjan Wouthuyzen-Bakker, Katharina Kusejko, Roger D. Kouyos, Giulia Scanferla, Ilker Uçkay, Martin Clauss, Prakhar Vijayvargiya, Álvaro Auñón

Publikováno v: Achermann, Yvonne; Kusejko, Katharina; Auñón, Álvaro; Clauss, Martin; Corvec, Stéphane; Esteban, Jaime; Fernandez-Sampedro, Marta; Ferrari, Matteo Carlo; Gassmann, Natalie; Jent, Philipp; Jost, Bernhard; Kouyos, Roger D; Kramer, Tobias Siegfried; Lora-Tamayo, Jaime; Morand, Philippe C; Benito, Natividad; Pablo-Marcos, Daniel; Patel, Robin; Scanferla, Giulia; Sendi, Parham; ... (2021). The impact of surgical strategy and rifampin on treatment outcome in Cutibacterium periprosthetic joint infections. Clinical infectious diseases, 72(12), e1064-e1073. Oxford University Press 10.1093/cid/ciaa1839
Clinical Infectious Diseases, 72(12), E1064-E1073. Oxford University Press
Clin Infect Dis

Background Cutibacterium species are common pathogens in periprosthetic joint infections (PJI). These infections are often treated with β-lactams or clindamycin as monotherapy, or in combination with rifampin. Clinical evidence supporting the value

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26aaa37d0a8664b74ce69c9005519337
https://boris.unibe.ch/150566/1/Unbenannt.pdf